Foresite Capital announced the appointment of Dr. Molly as a venture partner of the firm a few days ago. Dr. Molly was a senior director at Illumina. She has many years of experience in the pharmaceutical industry. Foresite is a growth equity firm that focuses on the healthcare industry. Jim Tananbaum is the managing director and chief executive officer of Foresite Capital. He pointed out that Dr. Molly is a respected researcher in the field of next-generation sequencing. He said that everyone at the firm was excited about her addition to the team. Jim stated that Molly’s leadership skills and her expertise in genomics are the factors that they looked at when they decided to appoint her. Tananbaum also said that Molly would play a huge role in diversifying the firm’s portfolio of companies.
Dr. Molly oversaw protein reagent research and innovation as the senior director at Illumina. She worked as the head of protein sciences at Pacific Biosciences before joining Illumina. Molly attended Nankai University where she graduated with a degree in biochemistry. She earned her Ph.D. in Protein Biophysics from the University of California. Molly has written numerous scientific papers. She has twenty patents to her name in personalized medicine and sequencing. Dr. Molly recognized Foresite’s reputation for investing in promising companies in the healthcare field at the time of the announcement. She added that she was excited to be a part of the team responsible for growing the firm’s portfolio. She finished by stating that sequencing had the potential to revolutionize clinical research and drug discovery. The headquarters of the enterprise is in San Francisco. It has another office in New York. Sourced info: Insidermonkey.com
According to Businesswire, Jim Tananbaum started Foresite Capital Management in 2010. He is its founding CEO. Tananbaum attended Yale University where he earned degrees in Science and Electrical Engineering. He went on to join Harvard where he earned an M.B.A and a Master’s degree in Medicine. He is known for starting GelTex Pharmaceuticals that was sold to Genzyme for close to two billion dollars. Jim has helped the company to invest in more than 20 healthcare companies including Jazz Pharmaceuticals, Amerigroup, and Amira Pharmaceuticals. He has served on the boards of the Yale School of Engineering and the Harvard-MIT HST program. More details can be found on Researchgate.